New clinical trial results presented by TB Alliance at the Union World Conference on Lung Health show that the novel ...

Clinical trial results found that a new antibiotic candidate could shorten TB treatment from the standard 6 months to 8 weeks ...

A new TB drug, sorfequiline, shows promising results in a multinational trial, raising hopes for faster and simpler treatment ...

An international team of investigators today announced promising data from a trial of a novel antibiotic that could ...

Positive results mark an important step forward in efforts to develop effective treatments for children with drug-resistant TB COPENHAGEN, Denmark, Nov. 19, 2025 /PRNewswire/ -- New interim data from ...

NEW YORK, May 14, 2014 /PRNewswire-USNewswire/ -- TB Alliance, a not-for-profit organization dedicated to developing better, faster, and affordable treatments for tuberculosis (TB), announced the ...

Researchers in the TB Alliance informed the Union Conference on Lung Health in Copenhagen that Sorbequiline, a new antibiotic ...

The Global Alliance for TB Drug Development (TB Alliance) and Bayer Healthcare AG today announced a partnership to coordinate a global clinical trial program to study the potential of an existing ...

In an ambitious effort to stem the dangerous tide of tuberculosis (TB) and deadly drug-resistant TB around the world, TB Alliance today announced that it has launched a first-of-its-kind clinical ...

Collaboration will focus on the development of TMC207 and the discovery of new drugs to treat tuberculosis [Seattle, WA] A new landmark collaboration between the Global Alliance for TB Drug ...

TB Alliance, a New York based global not-for-profit organization, has appointed Ratan P Watal to its board of directors. Welcoming Ratan Watal, the CEO of TB Alliance, Melvin Spigelman, said, “We are ...

(Reuters) - The U.S. Food and Drug Administration has approved TB Alliance's treatment for drug-resistant tuberculosis as part of a three-drug combination regimen called BPaL, the not-for-profit said ...